Details for Patent: 5,840,763

Title:	Treatment of a latent infection of herpes viruses
Abstract:	A method for the treatment of latent infection of herpesviruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A): ##STR1## or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.
Inventor(s):	Field; Hugh John (Cambridge, GB2), Thackray; Alana Maureen (Cambridge, GB2), Bacon; Teresa Helen (Weybridge, GB2), Sutton; David (Wayne, PA), Vere Hodge; Richard Anthony (Reigate, GB2)
Assignee:	SmithKline Beecham plc (Brentford, GB)
Filing Date:	Sep 01, 1995
Application Number:	08/522,790
Claims:	1. A method for reducing reactivation of a latent infection of herpes viruses in a human in need thereof which method comprises administering to said human an effective amount of famciclovir, or penciclovir, or a pharmaceutically acceptable salt thereof, at greater than 18 hours post-infection. 2. A method according to claim 1 wherein the treatment is for latent infection of herpes simplex type 1 infection. 3. A method according to claim 1 wherein the treatment is for latent infection of herpes simplex type 2 infection. 4. A method according to claim 1 wherein famciclovir is administered at a dose of 125 mg, 250 mg, 500 mg, 750 mg, or 1 g, once, twice or three times a day. 5. The method according to claim 1 wherein the time of administration is four (4) days or greater post-infection. 6. The method according to claim 1 wherein the length of time for reduction of the latent herpes viruses is from 3 to 14 days. 7. A method for the reducing the amount of, or eliminating the establishment of, a latent infection of herpes viruses in a human in need thereof which method comprises administering to said human an effective amount of famciclovir, or penciclovir, or a pharmaceutically acceptable salt thereof, at greater than 18 hours post-infection. 8. The method according to claim 7 wherein the latent herpes viral infection is HSV-1. 9. The method according to claim 7 wherein the latent herpes viral infection is HSV-2. 10. The method according to claim 7 wherein famciclovir is administered at a dose of 125 mg, 250 mg, 500 mg, 750 mg, or 1 g, once, twice or three times a day. 11. The method according to claim 7 wherein the time of administration is four (4) days or greater post-infection. 12. The method according to claim 7 wherein the length of time for reduction of the latent herpes viruses is from 3 to 14 days.